scholarly journals Flavoxate Hydrochloride

2020 ◽  
Author(s):  
Keyword(s):  
Flavoxate Hydrochloride

scholarly journals Polymeric Matrix Membrane Sensors for Stability-Indicating Potentiometric Determination of Oxybutynin Hydrochloride and Flavoxate Hydrochloride Urogenital System Drugs

2008 ◽  
Vol 91 (6) ◽  
pp. 1318-1330 ◽  
Author(s):  
Mohamed Heba ◽  
Nesrin Ramadan ◽  
Moustafa El-Laithy
Keyword(s):  
Degradation Products ◽  
Pharmaceutical Formulations ◽  
Official Method ◽  
Urogenital System ◽  
Electroactive Materials ◽  
Significant Difference ◽  
Ph Range ◽  
Oxybutynin Hydrochloride ◽  
Flavoxate Hydrochloride

Abstract Four polyvinyl chloride (PVC) matrix membrane electrodes responsive to 2 drugs affecting the urogenital systemoxybutynin hydrochloride (OX) and flavoxate hydrochloride (FX)were developed, described, and characterized. A precipitation-based technique with tungstophosphate (TP) and ammonium reineckate (R) anions as electroactive materials in a PVC matrix with an OX cation was used for electrode 1 and 2 fabrication, respectively. Electrode 3 and 4 fabrication was based on use of the precipitation technique of FX cation with tetrakis (4-chlorophenyl) borate and R anions as electroactive materials. Fast and stable Nernstian responses in the range 1 1021 106 M for the 2 drugs over the pH range 58 revealed the performance characteristics of these electrodes, which were evaluated according to International Union of Pure and Applied Chemistry recommendations. The method was applied to FX and OX in their pharmaceutical formulations and in human plasma samples. The 4 proposed sensors were found to be specific for the drugs in the presence of up to 60 of their degradation products. Validation of the method according to the quality assurance standards showed suitability of the proposed electrodes for use in the quality control assessment of these drugs. The recoveries for determination of the drugs by the 4 proposed selective electrodes were 99.5 0.5, 100.0 0.4, 99.9 0.4, and 100.1 0.4 for sensors 14, respectively. Statistical comparison between the results obtained by this method and the official method of the drugs was done, and no significant difference found.

Flavoxate Hydrochloride for Urinary Urgency after Pelvic Radiotherapy: Comparison of 600 mg versus 1200 mg Daily Dosages

1988 ◽  
Vol 16 (1) ◽  
pp. 71-74 ◽  
Author(s):  
R. Milani ◽  
S. Scalambrino ◽  
S. Carrera ◽  
P. Pezzoli ◽  
R. Ruffmann
Keyword(s):  
Bladder Capacity ◽  
Treatment Interruption ◽  
Urinary Urgency ◽  
Double Blind Trial ◽  
Pelvic Radiotherapy ◽  
Double Blind ◽  
Blind Trial ◽  
Preliminary Communication ◽  
Flavoxate Hydrochloride

This preliminary communication reports on a non-randomized pilot type trial of 34 females with urgency after pelvic radiotherapy who were treated with flavoxate hydrochloride for 4 weeks. A dosage of 600 mg/day was given to 21 patients and 1200 mg/day to 13 patients. Clinically, both regimens achieved comparable results. Urodynamically (first desire volume, bladder capacity and pressure at capacity) treatment with 1200 mg/day was significantly superior to 600 mg/day. Both schedules were equally well tolerated by patients and no treatment interruption occurred. A randomized double-blind trial comparing 600 and 1200 mg/day flavoxate hydrochloride is currently underway the results of which will be reported in due course.

scholarly journals The effects of flavoxate hydrochloride on voltage-dependent L-type Ca2+ currents in human urinary bladder

2005 ◽  
Vol 146 (1) ◽  
pp. 25-32 ◽  
Author(s):  
Toshihisa Tomoda ◽  
Manami Aishima ◽  
Naruaki Takano ◽  
Toshiaki Nakano ◽  
Narihito Seki ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Human Urinary Bladder ◽  
Voltage Dependent ◽  
Flavoxate Hydrochloride

Comparison of Flavoxate Hydrochloride in Daily Dosages of 600 versus 1200 mg for the Treatment of Urgency and Urge Incontinence

1988 ◽  
Vol 16 (3) ◽  
pp. 244-248 ◽  
Author(s):  
R. Milani ◽  
S. Scalambrino ◽  
S. Carrera ◽  
P. Pezzoli ◽  
R. Ruffmann
Keyword(s):  
Quality Of Life ◽  
Side Effect ◽  
Urge Incontinence ◽  
Double Blind ◽  
Free Treatment ◽  
Parallel Group ◽  
Flavoxate Hydrochloride ◽  
Parallel Group Trial ◽  
Group Trial

Flavoxate hydrochloride at a daily dosage of 600 mg was compared to a daily dosage of 1200 mg for the treatment of unstable bladder. Twenty-seven patients were treated for 4 weeks in a double-blind, randomized, parallel-group trial. Clinically, both schedules were equally successful. In urodynamic terms, however, particularly with respect to uninhibited detrusor contractions, 1200 mg/day was significantly superior to 600 mg/day. Tolerability was excellent for both regimens. The side-effect free treatment of urgency and urge incontinence is of paramount importance for a patient's quality of life.

Sign in / Sign up

Export Citation Format

Share Document